Ocean Biomedical

General Information
Business:

We are a biopharmaceutical company that seeks to bridge the “bench-to-bedside” gap between medical research discoveries and patient solutions. We do this by leveraging our strong relationships with research universities and medical centers to license their inventions and technologies with the goal of developing them into products that address diseases with significant unmet medical needs. Our current active assets are licensed directly or indirectly from Brown University, Stanford University and Rhode Island Hospital. Our scientific co-founders, Dr. Jack A. Elias and Dr. Jonathan Kurtis, are both affiliated with Brown University and Rhode Island Hospital.

We are pursuing programs in oncology, fibrosis, infectious disease and inflammation. Our programs in oncology and fibrosis are based on exclusive licenses with Brown University. Our programs in infectious disease are based on exclusive licenses with Rhode Island Hospital. Our program in inflammation is based on a nonexclusive license with Stanford University. We are not aware of any other licensee for these programs. We anticipate moving certain preclinical product candidates in our oncology (non-small cell lung cancer and glioblastoma multiforme, an aggressive type of brain cancer), pulmonary fibrosis and/or infectious disease (malaria) programs into the clinic in the next 12 to 18 months. We also expect our anti-inflammatory product candidate, OPS-172 targeting angiotensin 1-7, or Ang 1-7, to commence Phase 1/2 clinical trials for the treatment of COVID-19 in hospitalized patients in the second half of 2021.

(Note: Ocean Biomedical’s IPO pricing date is TBA. There was some talk that this IPO may get priced during the week of April 18, 2022, but that could not be confirmed after Easter weekend. The deal has been pushed back from pricing in February during Valentine’s week, and before that, the deal had been delayed from a pricing date in late July 2021. Ocean Biomedical drastically cut the size of its IPO in an S-1/A filing dated Feb. 4, 2022: The number of shares was cut to 2.0 million, down from 6.25 million in a July 26, 2021, filing with the SEC, and the price range was increased to $10 to $12, up from $7 to $9 in the July 2021 S-1/A filing. Under the new terms, the estimated IPO proceeds are $22 million. )

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 9
Founded: 2019
Contact Information
Address 55 Claverick St., Room 325, Providence, Rhode Island 02903
Phone Number (401) 444-7375
Web Address http://www.oceanbiomedical.com/
View Prospectus: Ocean Biomedical
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-45.56 mil (last 12 months)
IPO Profile
Symbol OCEA
Exchange NASDAQ
Shares (millions): 2.0
Price range $10.00 - $12.00
Est. $ Volume $22.0 mil
Manager / Joint Managers Roth Capital Partners/ JonesTrading
CO-Managers -
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change